Stockscreener 앱 받기
15.37
1.59%
0.24
시간 외 거래:
15.46
0.09
+0.59%
Summit Therapeutics Inc 주식(SMMT)의 최신 뉴스
AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics - citybiz
SMMT Inks Deal With AZN-Daiichi to Study Ivonescimab + Datroway Combos - Zacks Investment Research
Summit Therapeutics (NasdaqGM:SMMT) Stock Forecast & Analyst Predictions - Simply Wall Street
AstraZeneca (AZN) Puts $2 Billion Into Summit Therapeutics (SMMT) for a Cancer Tie-Up - Yahoo Finance
Summit Therapeutics Stock Climbs Wednesday: What's Happening? - Benzinga
AstraZeneca's $2 Billion Vote of Confidence Leaves Summit Therapeutics Trading Well Below Street Targets - 24/7 Wall St.
Roundup: Hengrui Pharma and Novo Enter Exclusive License Agreement for HRS-1596, AstraZeneca Enters Collaboartion with Summit Therapeutics - Pharmaceutical Executive
AstraZeneca Invests $2B in Summit for Cancer Drug Dev - Rediff MoneyWiz
Summit Therapeutics Soars Nearly 20% After AstraZeneca Bets $2 Billion on Cancer Drug Ivonescimab - Benzinga
Summit Therapeutics Shares Rise 22% After $2 Billion AstraZeneca Investment - Yahoo Finance
Summit Therapeutics Raises $2.0 Billion in Convertible Preferred Private Placement With AstraZeneca - TradingView
AstraZeneca invests $2bn in Summit Therapeutics to develop cancer drug - Business Weekly
AstraZeneca invests $2 billion in Summit Therapeutics in cancer drug deal - Proactive financial news
Summit Therapeutics agrees to US$2B AstraZeneca equity investment - Mugglehead Investment Magazine
AstraZeneca invests $2 billion in Summit Therapeutics By Investing.com - Investing.com
Summit Therapeutics rises after AstraZeneca commits $2B investment - TradingView
AstraZeneca announces strategic equity investment and clinical collaboration with Summit Therapeutics to advance leading ADC combination strategy in cancer - AstraZeneca
AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics - Business Wire
AstraZeneca invests $2 billion in Summit Therapeutics in cancer drug deal - Yahoo Finance UK
Summit Therapeutics (SMMT) Shows Promising Trial Results but Faces Valuation Challenges - GuruFocus
Summit’s ivonescimab cuts death risk by 27% versus Keytruda in lung cancer trial (SMMT:NASDAQ) - Seeking Alpha
Summit Therapeutics (SMMT) Gains Attention as Phase III Trial Data Boosts Outlook Amid Valuation Challenges - GuruFocus
Jefferies upgrades Summit Therapeutics stock rating on trial outlook By Investing.com - Investing.com South Africa
Summit Therapeutics Shares Rise After Upgrade From Jefferies - marketscreener.com
Summit Therapeutics shares gain after Jefferies upgrades stock to Buy - Yahoo Finance
Summit Therapeutics stock surges on Jefferies upgrade to buy By Investing.com - Investing.com Canada
Jefferies upgrades Summit Therapeutics stock rating on trial outlook By Investing.com - Investing.com Canada
Jefferies upgrades Summit Therapeutics stock rating on trial outlook By Investing.com - Investing.com UK
Summit Therapeutics Inc. (SMMT) Investor Outlook: Exploring A Potential 61.45% Upside - DirectorsTalk Interviews
Summit Therapeutics (SMMT) Soars 28% on Ivonescimab Progress - Yahoo Finance
Ivonescimab Demonstrates an Overall Survival Benefit in Advanced NSCLCSummit Therapeutics - Oncodaily
Why Summit Therapeutics (SMMT) Is Up 19.5% After New Ivonescimab Phase III Survival DataAnd What's Next - simplywall.st
Summit Therapeutics: The High Stakes Of Translating China Clinical Data To The U.S. (SMMT) - Seeking Alpha
Why is Summit Therapeutics stock surging today? By Investing.com - Investing.com South Africa
Summit's Ivonescimab Beats Merck's Keytruda on Survival in Chinese Lung Cancer Trial - finance.biggo.com
Summit Therapeutics Says It Is Beating Merck With Its Cancer Drug - Barron's
Why Is Summit Therapeutics Stock Soaring Today?Summit Therapeutics (NASDAQ:SMMT) - Benzinga
Summit Therapeutics, HUTCHMED, Tesla And Other Big Stocks Moving Higher On Thursday - benzinga.com
Why is Summit Therapeutics stock surging today? - investing.com
Summit Therapeutics stock rises on positive survival data By Investing.com - Investing.com Nigeria
Ivonescimab shows statistically significant OS vs pembrolizumab in HARMONi-2, Summit Therapeutics notes - TradingView
Summit Therapeutics stock rises on positive survival data - Investing.com
Summit Therapeutics stock rises on positive survival data By Investing.com - Investing.com Canada
November 14 Is The Make-Or-Break Moment For Summit Therapeutics' Cancer Bet - Seeking Alpha
Summit Therapeutics (SMMT) Gains on Positive Phase III Trial Res - GuruFocus
Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in HARMONi-2 Study Conducted by Akeso in China - Yahoo Finance
Cantor Fitzgerald reiterates Summit Therapeutics stock rating - Investing.com
Weekly Recap: HARMONi Phase III PFS improvement and Bernstein upgrade - TradingView
Summit Therapeutics Inc. (SMMT) Stock Analysis: Assessing a Potential 107.71% Upside in Biotech - DirectorsTalk Interviews
Summit Therapeutics (SMMT) Stock Climbed, So What Is Behind The Move? - Yahoo Finance
3.37%
0.04%
자본화:
|
볼륨(24시간):